Literature DB >> 2515489

Similar risks of nephropathy in patients with type I or type II diabetes mellitus.

C Hasslacher1, E Ritz, P Wahl, C Michael.   

Abstract

It is commonly assumed that in patients the risks of developing nephropathy and uraemia are high in type I and low in type II diabetes mellitus. Since type II occurs mostly in elderly individuals with limited life expectancy and high cardiovascular mortality, the true risk may have been underestimated, as many patients do not survive to experience renal complications. To assess renal risk further, we evaluated all patients with type II and type I diabetes mellitus without severe secondary disease who were followed in the outpatient clinic between 1970 and 1985. The cumulative risk of proteinuria after 20 years of diabetes mellitus was 27% in type II and 28% in type I, the findings after 25 years were 57% and 46% respectively. The cumulative risk of renal failure, i.e. serum creatinine greater than 1.4 mg/dl, after 3 years of persisting proteinuria was 41% in both type II and type I, and after 5 years of proteinuria were 63% and 59% respectively. We conclude that the renal risk is similar in patients with type II and type I diabetes mellitus.

Entities:  

Mesh:

Year:  1989        PMID: 2515489     DOI: 10.1093/ndt/4.10.859

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  39 in total

Review 1.  [Nephropathy and hypertension in type II diabetes].

Authors:  E Ritz; K Bergis; K Strojek; C Keller
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 2.  Integrating albuminuria and GFR in the assessment of diabetic nephropathy.

Authors:  George Jerums; Sianna Panagiotopoulos; Erosha Premaratne; Richard J MacIsaac
Journal:  Nat Rev Nephrol       Date:  2009-07       Impact factor: 28.314

3.  Evaluation of genetic association and expression reduction of TRPC1 in the development of diabetic nephropathy.

Authors:  Dongying Zhang; Barry I Freedman; Milan Flekac; Elisabete Santos; Pamela J Hicks; Donald W Bowden; Suad Efendic; Kerstin Brismar; Harvest F Gu
Journal:  Am J Nephrol       Date:  2008-09-19       Impact factor: 3.754

4.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

5.  Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes.

Authors:  Samy Hadjadj; Bertrand Cariou; Frederic Fumeron; Elise Gand; Guillaume Charpentier; Ronan Roussel; Ahmed-Amine Kasmi; Jean-François Gautier; Kammel Mohammedi; Pierre Gourdy; Pierre-Jean Saulnier; Eva Feigerlova; Michel Marre
Journal:  Diabetologia       Date:  2016-01       Impact factor: 10.122

Review 6.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

7.  Adiponectin gene polymorphisms in Egyptian type 2 diabetes mellitus patients with and without diabetic nephropathy.

Authors:  Amal S El-Shal; Haidy E Zidan; Nearmeen M Rashad
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

8.  Effects of aggressive approach to the multiple risk factors for diabetic nephro-pathy on proteinuria reduction in diabetes type 2 patients.

Authors:  Belma Ascić-Buturović; Mirsad Kacila; Mehmed Kulić
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

9.  Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.

Authors:  Utpal Sen; Walter E Rodriguez; Neetu Tyagi; Munish Kumar; Soumi Kundu; Suresh C Tyagi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-09       Impact factor: 4.310

10.  Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.

Authors:  Khalid M Alkharfy
Journal:  Exp Diabetes Res       Date:  2009-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.